Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511690 | 0.90 | MEN1 (0.60) | FFAR1MEN1KMT2AMAPTATM | |
| SCHEMBL19006636 | 0.82 | FFAR1 (0.73) | FFAR1MEN1KMT2AFFAR4ALDH1A1 | |
| SCHEMBL11509661 | 0.81 | FFAR1 (0.63) | FFAR1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL11513070 | 0.80 | FFAR1 (0.57) | FFAR1MEN1KMT2AMAPTATM | |
| SCHEMBL11935890 | 0.79 | MEN1 (0.49) | FFAR1MEN1KMT2AMAPTATM | |
| SCHEMBL6078208 | 0.79 | MEN1 (0.57) | FFAR1MEN1KMT2AMAPTATM | |
| SCHEMBL11117945 | 0.79 | FFAR1 (0.62) | FFAR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL25760803 | 0.79 | FFAR1 (0.63) | FFAR1MEN1KMT2AFFAR4 | |
| SCHEMBL6154500 | 0.79 | INSR (0.59) | FFAR1MEN1KMT2AMAPTATM | |
| SCHEMBL9798992 | 0.78 | FFAR1 (0.68) | FFAR1MEN1KMT2AFFAR4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | FFAR1 4172/4885MEN1 4329/4885KMT2A 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.